Section Edited by Marcela V. Maus, MD, PhD
Immune cell therapies and cell engineering approaches, new targets, novel functionalities, clinical trial results, correlative studies in patients who have received cell-based therapies, novel engineering strategies (molecular switches, conditional expression, logic gating), gene-edited cells to knock out or knock in novel functions, synthetic gene circuits. Includes pre-clinical animal modeling (small and large) and clinical trials.
Preclinical proof of concept for VivoVec, a lentiviral-based platform for in vivo CAR T-cell engineeringKathryn R Michels, Alyssa Sheih, Susana A Hernandez, Alissa H Brandes, Don Parrilla, Blythe Irwin, Anai M Perez, Hung-An Ting, Christopher J Nicolai, Timothy Gervascio, Seungjin Shin, Mark D Pankau, Mason Muhonen, Jessica Freeman, Sarah GouldSee the full list of authors
14 March 2023
All-trans retinoic acid improves NSD2-mediated RARα phase separation and efficacy of anti-CD38 CAR T-cell therapy in multiple myelomaZiyi Peng, Jingya Wang, Jing Guo, Xin Li, Sheng Wang, Ying Xie, Hongmei Jiang, Yixuan Wang, Mengqi Wang, Meilin Hu, Qian Li, Yafei Wang, Jian-Qing Mi, Zhiqiang Liu
14 March 2023
CD47 expression is critical for CAR T-cell survival in vivoAlex N Beckett, Peter Chockley, Shondra M Pruett-Miller, Phuong Nguyen, Peter Vogel, Heather Sheppard, Giedre Krenciute, Stephen Gottschalk, Christopher DeRenzo
14 March 2023
Metabolic reprogramming via an engineered PGC-1α improves human chimeric antigen receptor T-cell therapy against solid tumorsKonstantinos Lontos, Yiyang Wang, Supriya K Joshi, Andrew T Frisch, McLane J Watson, Alok Kumar, Ashley V Menk, Yupeng Wang, Rachel Cumberland, Jason Lohmueller, Esteban Carrizosa, Benjamin Boyerinas, Greg M Delgoffe
13 March 2023
Anti-VEGF therapy improves EGFR-vIII-CAR-T cell delivery and efficacy in syngeneic glioblastoma models in miceXinyue Dong, Jun Ren, Zohreh Amoozgar, Somin Lee, Meenal Datta, Sylvie Roberge, Mark Duquette, Dai Fukumura, Rakesh K Jain
10 March 2023
Runx3-overexpression cooperates with ex vivo AKT inhibition to generate receptor-engineered T cells with better persistence, tumor-residency, and antitumor abilityJianghui Tang, Jianpeng Sheng, Qi Zhang, Yongtao Ji, Xun Wang, Junlei Zhang, Jiangchao Wu, Jinyuan Song, Xueli Bai, Tingbo Liang
27 February 2023
Synergistic therapeutic combination with a CAF inhibitor enhances CAR-NK-mediated cytotoxicity via reduction of CAF-released IL-6Young Eun Lee, Ga-Yeon Go, Eun-Young Koh, Han-Na Yoon, Minkoo Seo, Seung-Mo Hong, Ji Hye Jeong, Jin-Chul Kim, Duck Cho, Tae Sung Kim, Song Cheol Kim, Eunsung Jun, Mihue Jang
27 February 2023
Generation of TGFβR2(-1) neoantigen-specific HLA-DR4-restricted T cell receptors for cancer therapyNatalia Plewa, Lucia Poncette, Thomas Blankenstein
23 February 2023
TCR-engineered adoptive cell therapy effectively treats intracranial murine glioblastomaMaximilian O Schaettler, Rupen Desai, Anthony Z Wang, Alexandra J Livingstone, Dale K Kobayashi, Andrew T Coxon, Jay A Bowman-Kirigin, Connor J Liu, Mao Li, Diane E Bender, Michael J White, David M Kranz, Tanner M Johanns, Gavin P Dunn
20 February 2023
IL15 modification enables CAR T cells to act as a dual targeting agent against tumor cells and myeloid-derived suppressor cells in GBMMarkella Zannikou, Joseph T Duffy, Rebecca N Levine, Maggie Seblani, Qianli Liu, Aaron Presser, Victor A Arrieta, Christopher J Chen, Adam M Sonabend, Craig M Horbinski, Catalina Lee-Chang, Jason Miska, Maciej S Lesniak, Stephen Gottschalk, Irina V Balyasnikova
9 February 2023